Breast Tumor Detection and Treatment Using Tarvacin Labeled with Arsenic Radionuclides
Abstract
We will generate a novel approach for detection and therapy of advanced breast cancer based on three fundamentally novel discoveries and concepts. The first critical component exploits a novel antibody, which targets phosphatidylserine (PS), expressed on tumor vasculature. In collaboration with Peregrine Pharmaceuticals, this agent has been chimerized and is being developed for clinical trials as bavituximab (formerly TM). Normally, exclusively resides on the cytosolic leaflet of the plasma membrane, but in tumors PS becomes externalized providing a viable target. The agent not only targets various tumors, but also induces vascular damage and tumor regression with minimal accompanying toxicity. The second component is the identification of diverse arsenic radionuclides suitable for imaging based on PET and radio immunotherapy together with new means of isolating the radionuclides. Importantly, the antibodies can be effectively labeled forming viable products of high specific radiochemical and biological activity. Thirdly, our program brings together pharmacological and radiochemical expertise to facilitate collaboration, progress, and synergy. This project will develop a single agent (bavituximab) for tumor detection, dosimetry, and therapy based on differential properties of arsenic radionuclides, but exploiting a single chemistry.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 01, 2007
- Accession Number
- ADA470579
Entities
People
- Ralph P. Mason
Organizations
- University of Texas Southwestern Medical Center